Advanced lung adenocarcinoma (LUAD) patient with EGFR mutations benefited from multiline combination targeted therapies after osimertinib (AZD9291) resistance: a case report

BACKGROUND: The resistance mechanisms to osimertinib encompass on-target molecular alterations, such as the well-known epidermal growth factor receptor (EGFR) C797S resistance mutation, and off-target molecular alterations, such as the high-frequency MET amplification, but there’s no further clear-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jingyu, Zhao, Xueqi, Wang, Jinlin, Liu, Fangfang, Zhang, Linli, Chen, Yuan, Chu, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552262/
https://www.ncbi.nlm.nih.gov/pubmed/36237272
http://dx.doi.org/10.21037/tcr-22-510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552262/
https://www.ncbi.nlm.nih.gov/pubmed/36237272
http://dx.doi.org/10.21037/tcr-22-510

Ejemplares similares